Generic Revlimid Availability

Revlimid is a brand name of lenalidomide, approved by the FDA in the following formulation(s):

REVLIMID (lenalidomide - capsule;oral)

  • Manufacturer: CELGENE
    Approval date: December 27, 2005
    Strength(s): 5MG, 10MG
  • Manufacturer: CELGENE
    Approval date: June 29, 2006
    Strength(s): 15MG, 25MG [RLD]
  • Manufacturer: CELGENE
    Approval date: December 21, 2011
    Strength(s): 2.5MG
  • Manufacturer: CELGENE
    Approval date: June 5, 2013
    Strength(s): 20MG

Has a generic version of Revlimid been approved?

No. There is currently no therapeutically equivalent version of Revlimid available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Revlimid. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Method of reducing TNF.alpha. levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines
    Patent 5,635,517
    Issued: June 3, 1997
    Inventor(s): Muller; George W. & Stirling; David I. & Chen; Roger S. -C.
    Assignee(s): Celgene Corporation
    1-Oxo- and 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl) isoindolines substituted with amino in the benzo ring reduce the levels of TNF.alpha. in a mammal. A typical embodiment is 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-5-aminoisoindoline.
    Patent expiration dates:
    • October 4, 2019
      ✓ 
      Patent use: USE OF REVLIMID (LENALIDOMIDE) TO INHIBIT THE SECRETION OF PRO-INFLAMMATORY CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • October 4, 2019
      ✓ 
      Patent use: USE OF REVLIMID (LENALIDOMIDE) TO INHIBIT THE SECRETION OF PRO-INFLAMMATORY CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA
      ✓ 
      Drug substance
  • Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
    Patent 6,045,501
    Issued: April 4, 2000
    Inventor(s): Elsayed; Marc & Williams; Bruce
    Assignee(s): Celgene Corporation
    Novel methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug. Embodiments are provided in which the involved prescribers, pharmacies and patients are registered in one or more computer databases. Embodiments are also provided in which registered patients receive counseling information concerning the risks attendant to foetal exposure to the drug. Male patients and female patients who are not pregnant may, in certain circumstances, receive the drug.
    Patent expiration dates:
    • August 28, 2018
      ✓ 
      Patent use: USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE)
  • Isoindolines, method of use, and pharmaceutical compositions
    Patent 6,281,230
    Issued: August 28, 2001
    Inventor(s): Muller; George W. & Stirling; David I. & Chen; Roger Shen-Chu
    Assignee(s): Celgene Corporation
    Substituted 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines are useful in treating inflammation, inflammatory disease, autoimmune disease, and oncogenic or cancerous conditions in a mammal. Typical embodiments are 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline and 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4-aminoisoindoline.
    Patent expiration dates:
    • July 24, 2016
      ✓ 
      Patent use: USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL)
    • July 24, 2016
      ✓ 
      Patent use: USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA AND TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
  • Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
    Patent 6,315,720
    Issued: November 13, 2001
    Inventor(s): Williams; Bruce A. & Kaminski; Joseph K.
    Assignee(s): Celgene Corporation
    Improved methods for delivering to a patient in need of the drug, while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug are disclosed. The methods are of the type in which prescriptions for the drug are filled only after a computer readable storage medium has been consulted to assure that the prescriber, pharmacy and patient have been properly registered in the medium before the patient is approved to receive the drug. Embodiments are provided wherein the patients are assigned to risk groups based upon the risk that taking the drug will lead to the side effect, and certain additional information, such as periodic surveys and diagnostic tests probative of the ongoing risk of the side effect developing are obtained before prescriptions for the drug are approved.
    Patent expiration dates:
    • October 23, 2020
      ✓ 
      Patent use: USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE)
  • Isoindolines, method of use, and pharmaceutical compositions
    Patent 6,555,554
    Issued: April 29, 2003
    Inventor(s): George W.; Muller & David I.; Stirling & Roger Shen-Chu; Chen
    Assignee(s): Celgene Corporation
    Substituted 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines are useful in reducing undesirable levels of TNF&agr; in a mammal. Typical embodiments are pharmaceutical compositions containing 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline and 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4-aminoisoindoline.
    Patent expiration dates:
    • July 24, 2016
      ✓ 
      Patent use: USE OF REVLIMID (LENALIDOMIDE) TO INHIBIT THE SECRETION OF PRO-INFLAMMATORY CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA
      ✓ 
      Drug product
  • Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
    Patent 6,561,976
    Issued: May 13, 2003
    Inventor(s): Marc; Elsayed & Bruce; Williams
    Assignee(s): Celgene Corporation
    Novel methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug. Embodiments are provided in which the involved prescribers, pharmacies and patients are registered in one or more computer databases. Embodiments are also provided in which registered patients receive counseling information concerning the risks attendant to foetal exposure to the drug. Male patients and female patients who are not pregnant may, in certain circumstances, receive the drug.
    Patent expiration dates:
    • August 28, 2018
      ✓ 
      Patent use: USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE)
  • Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
    Patent 6,561,977
    Issued: May 13, 2003
    Inventor(s): Bruce A.; Williams & Joseph K.; Kaminski
    Assignee(s): Celgene Corporation
    Methods for delivering a drug to a patients in need of the drug, while restricting access to the drug by patients for whom the drug may be contraindicated are disclosed. The methods are of the type in which prescriptions for the drug are filled by a pharmacy only after a computer readable storage medium has been consulted to retrieve a prescription approval code. Embodiments are provided wherein the patients are assigned to risk groups based upon the risk that taking the drug will lead to an adverse side effect, and certain additional information, such as periodic surveys and diagnostic tests probative of the ongoing risk of the side effect developing are obtained before prescriptions for the drug are approved.
    Patent expiration dates:
    • October 23, 2020
      ✓ 
      Patent use: USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE)
  • Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
    Patent 6,755,784
    Issued: June 29, 2004
    Inventor(s): Bruce A.; Williams & Joseph K.; Kaminski
    Assignee(s): Celgene Corporation
    Methods for delivering a drug to a patients in need of the drug, while restricting access to the drug by patients for whom the drug may be contraindicated are disclosed. The methods are of the type in which prescriptions for the drug are filled by a pharmacy only after a computer readable storage medium has been consulted to retrieve a prescription approval code. Embodiments are provided wherein the patients are assigned to risk groups based upon the risk that taking the drug will lead to an adverse side effect, and certain additional information, such as periodic surveys and diagnostic tests probative of the ongoing risk of the side effect developing are obtained before prescriptions for the drug are approved.
    Patent expiration dates:
    • October 23, 2020
      ✓ 
      Patent use: USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE)
  • Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
    Patent 6,908,432
    Issued: June 21, 2005
    Inventor(s): Elsayed; Marc & Williams; Bruce
    Assignee(s): Celgene Corporation
    Novel methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug. Embodiments are provided in which the involved prescribers, pharmacies and patients are registered in one or more computer databases. Embodiments are also provided in which registered patients receive counseling information concerning the risks attendant to foetal exposure to the drug. Male patients and female patients who are not pregnant may, in certain circumstances, receive the drug.
    Patent expiration dates:
    • August 28, 2018
      ✓ 
      Patent use: USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE)
  • Pharmaceutical compositions of 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
    Patent 7,119,106
    Issued: October 10, 2006
    Inventor(s): Muller; George W. & Stirling; David I. & Chen; Roger Shen-Chu
    Assignee(s): Celgene Corporation
    Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines reduce the levels of TNFα in a mammal. Typical embodiments are 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4,5,6,7-tetrafuoroisoindoline and 1,3-dioxo-2-(2,6-dioxo-3 -methylpiperidin-3-yl)-4-aminoisoindoline.
    Patent expiration dates:
    • July 24, 2016
      ✓ 
      Drug product
  • Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
    Patent 7,189,740
    Issued: March 13, 2007
    Inventor(s): Zeldis; Jerome B.
    Assignee(s): Celgene Corporation
    Methods of treating, preventing and/or managing myclodysplastic syndromes are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active ingredient, and/or the transplantation of blood or cells. Specific second active ingredients are capable of affecting or blood cell production. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Patent expiration dates:
    • April 11, 2023
      ✓ 
      Patent use: USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
  • Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
    Patent 7,465,800
    Issued: December 16, 2008
    Inventor(s): Jaworsky; Markian S. & Chen; Roger Shen-Chu & Muller; George W.
    Assignee(s): Celgene Corporation
    Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.
    Patent expiration dates:
    • April 27, 2027
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Methods for treatment of cancers using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
    Patent 7,468,363
    Issued: December 23, 2008
    Inventor(s): Zeldis; Jerome B.
    Assignee(s): Celgene Corporation
    Methods of treating a specific cancer or amyloidosis are disclosed. Specific methods encompass the administration of 3-(4-amino-1 oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione alone or in combination with a second active ingredient.
    Patent expiration dates:
    • October 7, 2023
      ✓ 
      Patent use: USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL)
  • Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
    Patent 7,855,217
    Issued: December 21, 2010
    Inventor(s): Jaworsky; Markian S. & Chen; Roger Shen-Chu & Muller; George W.
    Assignee(s): Celgene Corporation
    Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.
    Patent expiration dates:
    • November 24, 2024
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
    Patent 7,968,569
    Issued: June 28, 2011
    Inventor(s): Zeldis; Jerome B.
    Assignee(s): Celgene Corporation
    Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Patent expiration dates:
    • October 7, 2023
      ✓ 
      Patent use: USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA
  • Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
    Patent 8,204,763
    Issued: June 19, 2012
    Inventor(s): Elsayed; Marc & Williams; Bruce
    Assignee(s): Celgene Corporation
    Novel methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug. Embodiments are provided in which the involved prescribers, pharmacies and patients are registered in one or more computer databases. Embodiments are also provided in which registered patients receive counseling information concerning the risks attendant to foetal exposure to the drug. Male patients and female patients who are not pregnant may, in certain circumstances, receive the drug.
    Patent expiration dates:
    • August 28, 2018
      ✓ 
      Patent use: TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG
  • Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione
    Patent 8,288,415
    Issued: October 16, 2012
    Inventor(s): Muller; George W. & Stirling; David I. & Chen; Roger Shen-Chu
    Assignee(s): Celgene Corporation
    Substituted 2-(2,6-dioxopiperidin-3-yl)phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines are disclosed. The compounds are useful, for example, in reducing the levels of TNFα in a mammal.
    Patent expiration dates:
    • July 24, 2016
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
    Patent 8,315,886
    Issued: November 20, 2012
    Inventor(s): Williams; Bruce A. & Kaminski; Joseph K.
    Assignee(s): Celgene Corporation
    Methods for delivering a drug to a patients in need of the drug, while restricting access to the drug by patients for whom the drug may be contraindicated are disclosed. The methods are of the type in which prescriptions for the drug are filled by a pharmacy only after a computer readable storage medium has been consulted to retrieve a prescription approval code. Embodiments are provided wherein the patients are assigned to risk groups based upon the risk that taking the drug will lead to an adverse side effect, and certain additional information, such as periodic surveys and diagnostic tests probative of the ongoing risk of the side effect developing are obtained before prescriptions for the drug are approved.
    Patent expiration dates:
    • October 23, 2020
      ✓ 
      Patent use: TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG
  • Methods of treating myelodysplastic syndromes using lenalidomide
    Patent 8,404,717
    Issued: March 26, 2013
    Assignee(s): Celgene Corporation
    Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administrations of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dione in combination with 5-azacytidine.
    Patent expiration dates:
    • April 11, 2023
      ✓ 
      Patent use: USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)
  • Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione
    Patent 8,530,498
    Issued: September 10, 2013
    Assignee(s): Celgene Corporation
    Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Patent expiration dates:
    • May 15, 2023
      ✓ 
      Patent use: USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA
  • Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
    Patent 8,589,188
    Issued: November 19, 2013
    Assignee(s): Celgene Corporation
    Novel methods for delivering a drug to a patient while preventing the exposure of a fetus or other contraindicated individual to the drug. Embodiments are provided in which the involved prescribers, pharmacies and patients are registered in one or more computer databases. Embodiments are also provided in which registered patients receive counseling information concerning the risks attendant to fetal exposure to the drug. Male patients and female patients who are not pregnant may, in certain circumstances, receive the drug.
    Patent expiration dates:
    • August 28, 2018
      ✓ 
      Patent use: USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE)
  • Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
    Patent 8,626,531
    Issued: January 7, 2014
    Assignee(s): Celgene Corporation
    Methods for delivering a drug to a patients in need of the drug, while restricting access to the drug by patients for whom the drug may be contraindicated are disclosed. The methods are of the type in which prescriptions for the drug are filled by a pharmacy only after a computer readable storage medium has been consulted to retrieve a prescription approval code. Embodiments are provided wherein the patients are assigned to risk groups based upon the risk that taking the drug will lead to an adverse side effect, and certain additional information, such as periodic surveys and diagnostic tests probative of the ongoing risk of the side effect developing are obtained before prescriptions for the drug are approved.
    Patent expiration dates:
    • October 23, 2020
      ✓ 
      Patent use: USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE)
  • Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor
    Patent 8,648,095
    Issued: February 11, 2014
    Assignee(s): Celgene Corporation
    Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Patent expiration dates:
    • May 15, 2023
      ✓ 
      Patent use: USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • June 5, 2016 - USE IN PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB
    • June 5, 2016 -
    • June 5, 2020 -

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web3)